Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Gijsbert Veerman

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Cultured Tumor Cells

Living Beings

Disorders

Physiology

Procedures

Phenomena

Drug Synergism

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
33
Peters, Godefridus
19
Ruiz van Haperen, Veronique
17
PINEDO, HERBERT
16
Bergman, André
13
Vermorken, Jan
12
Van Moorsel, Catharina
8
Kuiper, CM
7
Smid, Kees
7
Voorn, Daphne
5
Postmus, Pieter
5
Braakhuis, Boudewijn
4
Boven, Epie
4
Kroep, Judith
3
Noordhuis, Paul
3
van der Vijgh, Wim

Sign-in to see all Coauthors

Publications

TOP 3
Smid K; Bergman A M; Eijk P P; Veerman G; van Haperen V W T Ruiz; van den Ijssel P; Ylstra B; Peters G J
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
Bergman Andries M; Eijk Paul P; Ruiz van Haperen Veronique W T; Smid Kees; Veerman Gijsbert; Hubeek Isabelle; van den Ijssel Paul; Ylstra Bauke; Peters Godefridus J
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Bergman A M; Pinedo H M; Talianidis I; Veerman G; Loves W J P; van der Wilt C L; Peters G J
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Gijsbert Veerman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2006: Smid K; Bergman A M; Eijk P P; Veerman G; van Haperen V W T Ruiz; van den Ijssel P; Ylstra B; Peters G J
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
Nucleosides, nucleotides & nucleic acids 2006;25(9-11):1001-7.
2005: Bergman Andries M; Eijk Paul P; Ruiz van Haperen Veronique W T; Smid Kees; Veerman Gijsbert; Hubeek Isabelle; van den Ijssel Paul; Ylstra Bauke; Peters Godefridus J
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Cancer research 2005;65(20):9510-6.
2003: Bergman A M; Pinedo H M; Talianidis I; Veerman G; Loves W J P; van der Wilt C L; Peters G J
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
British journal of cancer 2003;88(12):1963-70.
2001: Bergman A M; Munch-Petersen B; Jensen P B; Sehested M; Veerman G; Voorn D A; Smid K; Pinedo H M; Peters G J
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Biochemical pharmacology 2001;61(11):1401-8.
2001: van der Wilt C L; Backus H H; Smid K; Comijn L; Veerman G; Wouters D; Voorn D A; Priest D G; Bunni M A; Mitchell F; Jackman A L; Jansen G; Peters G J
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
Cancer research 2001;61(9):3675-81.
2000: van Moorsel C J; Pinedo H M; Smid K; Comijn E M; Voorn D A; Veerman G; Lakerveld B; Van der Vijgh W J; Giaccone G; Postmus P E; Peters G J
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2420-9.
2000: van Moorsel C J; Bergman A M; Veerman G; Voorn D A; Ruiz van Haperen V W; Kroep J R; Pinedo H M; Peters G J
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
Biochimica et biophysica acta 2000;1474(1):5-12.
1999: van Moorsel C J; Pinedo H M; Veerman G; Bergman A M; Kuiper C M; Vermorken J B; van der Vijgh W J; Peters G J
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
British journal of cancer 1999;80(7):981-90.
1999: van Moorsel C J; Pinedo H M; Veerman G; Vermorken J B; Postmus P E; Peters G J
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
European journal of cancer (Oxford, England : 1990) 1999;35(5):808-14.
1999: van Moorsel C J; Kroep J R; Pinedo H M; Veerman G; Voorn D A; Postmus P E; Vermorken J B; van Groeningen C J; van der Vijgh W J; Peters G J
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):441-8.
1999: van Moorsel C J; Pinedo H M; Veerman G; Guechev A; Smid K; Loves W J; Vermorken J B; Postmus P E; Peters G J
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Biochemical pharmacology 1999;57(4):407-15.
1999: Bergman A M; Pinedo H M; Jongsma A P; Brouwer M; Ruiz van Haperen V W; Veerman G; Leyva A; Eriksson S; Peters G J
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Biochemical pharmacology 1999;57(4):397-406.
1998: Smitskamp-Wilms E; Pinedo H M; Veerman G; Ruiz van Haperen V W; Peters G J
Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
European journal of cancer (Oxford, England : 1990) 1998;34(6):921-6.
1998: van Moorsel C J; Veerman G; Ruiz van Haperen V W; Bergman A M; Jensen P B; Sehested M; Peters G J
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines.
Advances in experimental medicine and biology 1998;431():661-5.
1998: Kroep J R; van Moorsel C J; Veerman G; Voorn D A; Schultz R M; Worzalla J F; Tanzer L R; Merriman R L; Pinedo H M; Peters G J
Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Advances in experimental medicine and biology 1998;431():657-60.
1998: van der Wilt C L; Smid K; Veerman G; Peters G J
The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracil.
Advances in experimental medicine and biology 1998;431():653-6.
1998: Ruiz van Haperen V W; Veerman G; van Moorsel C J; Peters G J
Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Advances in experimental medicine and biology 1998;431():637-40.
1998: Bergman A M; Pinedo H M; Veerman G; Kuiper C M; Peters G J
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines.
Advances in experimental medicine and biology 1998;431():591-4.
1998: Bergman A M; Pinedo H M; Ruiz van Haperen V W; Veerman G; Kuiper C M; Peters G J
Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Advances in experimental medicine and biology 1998;431():587-90.
1998: van Moorsel C J; Veerman G; Vermorken J B; Voorn D A; Kroep J R; Bergman A M; Pinedo H M; Peters G J
Mechanisms of synergism between gemcitabine and cisplatin.
Advances in experimental medicine and biology 1998;431():581-5.
1997: van Moorsel C J; Veerman G; Bergman A M; Guechev A; Vermorken J B; Postmus P E; Peters G J
Combination chemotherapy studies with gemcitabine.
Seminars in oncology 1997;24(2 Suppl 7):S7-17-S7-23.
1996: Peters G J; Ruiz van Haperen V W; Bergman A M; Veerman G; Smitskamp-Wilms E; van Moorsel C J; Kuiper C M; Braakhuis B J
Preclinical combination therapy with gemcitabine and mechanisms of resistance.
Seminars in oncology 1996;23(5 Suppl 10):16-24.
1996: van Haperen V W; Veerman G; Vermorken J B; Pinedo H M; Peters G
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
Biochemical pharmacology 1996;51(7):911-8.
1996: Bergman A M; Ruiz van Haperen V W; Veerman G; Kuiper C M; Peters G J
Synergistic interaction between cisplatin and gemcitabine in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):521-30.
1996: Veerman G; Ruiz van Haperen V W; Vermorken J B; Noordhuis P; Braakhuis B J; Pinedo H M; Peters G J
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Cancer chemotherapy and pharmacology 1996;38(4):335-42.
1995: Peters G J; Bergman A M; Ruiz van Haperen V W; Veerman G; Kuiper C M; Braakhuis B J
Interaction between cisplatin and gemcitabine in vitro and in vivo.
Seminars in oncology 1995;22(4 Suppl 11):72-9.
1995: Braakhuis B J; Ruiz van Haperen V W; Boven E; Veerman G; Peters G J
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Seminars in oncology 1995;22(4 Suppl 11):42-6.
1995: Ruiz van Haperen V W; Veerman G; Eriksson S; Stegmann A P; Peters G J
Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Seminars in oncology 1995;22(4 Suppl 11):35-41.
1995: Gielen M; Willem R; Bouhdid A; De Vos D; Kuiper C M; Veerman G; Peters G J
In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of five organotin compounds.
In vivo (Athens, Greece) 1995;9(1):59-63.
1994: Ruiz van Haperen V W; Veerman G; Boven E; Noordhuis P; Vermorken J B; Peters G J
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Biochemical pharmacology 1994;48(7):1327-39.
1994: Ruiz van Haperen V W; Veerman G; Eriksson S; Boven E; Stegmann A P; Hermsen M; Vermorken J B; Pinedo H M; Peters G J
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Cancer research 1994;54(15):4138-43.
1994: Bergman A M; Ruiz van Haperen V W; Veerman G; Kuiper C M; Peters G J
Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
Advances in experimental medicine and biology 1994;370():139-43.
1993: Ruiz van Haperen V W; Veerman G; Vermorken J B; Peters G J
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
Biochemical pharmacology 1993;46(4):762-6.
1993: Ruiz van Haperen V W; Veerman G; Braakhuis B J; Vermorken J B; Boven E; Leyva A; Peters G J
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2132-7.
1991: Ruiz van Haperen V W; Veerman G; Noordhuis P; Vermorken J B; Peters G J
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
Advances in experimental medicine and biology 1991;309A():57-60.

Sign-in to see more